首页>投融资
Antiva Biosciences
E~PreIPO
Antiva Biosciences is focused on the research, development and commercialization of localized antivirals for infections with human papillomavirus (HPV).In April 2023, Antiva Biosciences closed a $53 million Series E equity financing.In November 2021, Antiva Biosciences closed a $31 million Series D equity financing.In July 2018, the company raised $15 million in Series C-1 financing.In March 2017, the company raised $22 million in a Series C financing round.In August 2015, the company raised $16 million through a series B financing
基本信息
-
公司全称Antiva Biosciences Inc
-
类型生物制药公司
-
产业领域医药研发/制造、化学&生物药
-
公司人数不明确
-
地址280 OLD COUNTY ROAD #257 BRISBANE CALIFORNIA 94005; US; Telephone: +16508221400;
-
联系电话(650)822-1400
-
邮箱info@antivabio.com
-
成立时间
投融资
-
2023-04-27E~PreIPO5300万美元GVBioImpact CapitalCanaan PartnersSofinnova PartnersAdjuvant CapitalLumira Ventures
-
2021-11-02D轮3100万美元GaingelsAlexandria Venture InvestmentsGVCanaan PartnersHBM HealthcareDong-A STMana VenturesAvestria VenturesAdjuvant CapitalOsage University PartnersBrace Pharma CapitalLumira VenturesSirona CapitalSofinnova Partners
-
2018-07-11C轮1500万美元Canaan PartnersOsage University PartnersBrace Pharma CapitalSirona CapitalLumira CapitalSofinnova Partners
-
2017-03-30C轮2200万美元Alexandria Venture InvestmentsCanaan PartnersOsage University PartnersBrace Pharma CapitalTimefolio CapitalSofinnova Partners
-
2015-08-01B轮1600万美元Canaan PartnersSofinnova Partners
-
2014-12-23A轮175万美元未透露
-
2014-07-10债权融资110万美元未透露
-
2013-06-12天使轮51.101万美元未透露
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息